McBride plc

19 November 2026

Cost inflation takes its toll, for now

Sustained global geo-political tensions have led to persistent input cost inflation for McBride, which has led to a further delay in margin recovery actions. This has taken its toll on FY27E profits, and to some extent FY28E, we forecast. Yet economic pressure means private label products remain in demand and strategically we believe McBride is in a robust position, particularly following the acquisition of Eurotab and the contract manufacturing partnership with Vestacy. Hence, whilst we reduce our fair value per share by 13% to 230p (equivalent to c.11x cal 2027 PER), we still believe McBride's rating materially undervalues the group.

FY27E EBITA to be 20%-25% below consensus expectations

When McBride reported its FY26 results in September, it warned that raw material prices were likely to rise further and that it was ready to mitigate the impact quickly with further price action. However, this has proved optimistic as inflationary pressures have endured far longer than expected. Combined with some operational challenges, that are now mostly resolved, the Board now "anticipates that recovery of margins towards previous levels will be during Q4 2027 (previously Q2 2027)". Consequently, management expects FY27E Adj. EBITA to be c.£47m-£50m. We reduce our FY27E Adj. EBIT by 21.5% to £48.4m and Adj. PBT by 27% to £35.4m, reflecting a c.120bps hit to operating margin to 4.7%. The Board expects the current margin pressures to resolve over time, but we prudently reduce our FY28E and FY29E Adj. PBT forecasts by 15% and 12% respectively.

Market leader strength with Eurotab acquisition and Vestacy partnership

Whilst the weak macro-economic situation persists, McBride's strategic momentum has continued with product innovation and structural cost savings. In addition, McBride acquired Eurotab in April for €40m and announced a £170m contract manufacturing partnership with Vestacy in August, both of which are earnings enhancing and their integrations are on track.

Fair Value per share reduced 13% to 230p

Whilst we reflect the cash impact of the margin hit and reduce our Fair Value to 230p per share, we believe McBride's market leadership strength and high ROCE are not fully appreciated in its rating.

Key financials & valuation metrics

Year to 30 June (£m)	2025	2026	2027E	2028E	2029E
Revenue	926.5	934.2	1,028.0	1,143.4	1,204.8
Revenue growth (%)	*-0.9*	*0.8*	*10.0*	*11.2*	*5.4*
Adj. PBT	54.9	48.8	35.4	56.1	65.3
Adj. PBT margin (%)	*5.9*	*5.2*	*3.4*	*4.9*	*5.4*
Adj. diluted EPS (p)	21.1	20.6	15.9	25.5	28.5
Dividend per share (p)	3.0	3.1	3.1	4.5	5.0
Adj. operating free cashflow	93.9	56.7	56.4	90.5	99.4
Free cashflow	28.9	(2.0)	(44.7)	20.5	23.3
Net cash / (debt) /Adj. EBITDA (x)	(1.2)	(1.5)	(2.7)	(1.8)	(1.6)
EV / Sales (x, calendarised)		0.4	0.4	0.4	
PER (x, calendarised)		9.6	8.5	6.5	
Dividend yield (%, calendarised)		1.8	2.2	2.7	
Free cashflow yield (%, calendarised)		-1.9	1.6	7.0	

Source: Company data, Equity Development, Priced as at 18 November 2026

Company data

EPIC	MCB
Price (last close)	175.8p
52 weeks Hi/Lo	212p/120p
Market cap	£305m
ED Fair Value / share	230p
Net cash / (debt) 2026	£(123m)
Avg. daily volume (3m)	297k

Share price, p



Source: Investing.com

Description

McBride plc ("McBride") is the European market leader in private label and contract manufactured household cleaning products.

It manufactures from 17 factories (including 3 acquired with Eurotab): 15 across Europe and one each in Malaysia and Vietnam. McBride supplies 90% of the top 50 European grocery retailers, generating £934m revenues in FY26.

Next event

H127 trading update - Jan 2027 (tbc)

Caroline Gulliver (Analyst)
0207 065 2690
caroline.gulliver@equitydevelopment.co.uk

Andy Edmond
0207 065 2691
andy@equitydevelopment.co.uk

Please refer to the important disclosures shown on the back page and note that this information is **Non-independent** and categorised as **Marketing Material**

Contents

Why invest in McBride? 3
A profitable and cashflow generative market leader in private label household cleaning 4
Strategically important acquisition of Eurotab group… 5
…and an important contract manufacturing partnership with Vestacy 6
An underrated business with high returns, despite pricing time lag hitting profits 7

Financial Forecast tables 8

Why invest in McBride?

Investment Highlights

- McBride is the European market leader in private label household cleaning products with a c.30% market share, c. 2x its nearest competitor. The company is proud of its reputation for expertly making everyday value cleaning products.
- The group has recovered from unprecedented high-cost inflation in 2022 and grown revenues to over £930m and adj. operating profits of c.£60m+, a 6%-7% margin (FY24-FY26).
- Private-label penetration of the European market has stabilised at c.35% of volumes but there are growth opportunities for McBride from product innovation, winning new contracts and building share in certain product markets (e.g. Laundry) and geographies (e.g. Germany and Spain).
- McBride has a strong focus on sustainability and innovation to reduce carbon and non-recyclable packaging. As such, McBride is the only major private label player signed up to science-based targets ("SBT").

Risk Factors

- Rapid high-cost inflation, though having been through this in 2022 and introduced input cost hedges and quarterly pricing reviews there would be less of a time lag between passing cost inflation on in prices now (i.e. 3 months).
- Irrational competitive pricing behaviour, from either branded producers or smaller private label producers.
- Loss of a major contract with a large supermarket chain (though McBride has over 150 customers and the top 10 customers account for only 54% of revenues).
- Supply chain disruption, leading to a drop in customer service levels ("CSL") though having 17 factories across Europe and Asia diversifies this risk.
- Technology disruption, though the roll out of the latest ERP software is progressing to plan.
- Brand reputation risk, for product health or sustainability issues or other reasons.

Forecast Drivers

- The group's tailored divisional strategies underpin our group organic revenue growth of 1%-2% FY26E-FY28E which is a mix of volume growth and price investment/product mix. Eurotab adds c.6% in FY27E and Vestacy adds c. 16% by FY29E.
- Although we forecast input cost inflation leading to Adj. operating profit falling to c.£48m in FY27E (4.7% margin), we anticipate some margin recovery actions driving operating profit margin back above 6% from FY28E.
- We forecast high conversion of Adj. EBITDA to adj. operating free cashflow of £50m-£100m (FY27E-FY29E). This funds capex of c.£30m-£40m p/a, the reinstated dividend, a £20m share buy-back, the acquisition of Eurotab (£34.5m) and investment in the Vestacy partnership (£17m).

Valuation Overview


- Prior to the profit warning today, McBride was trading on only 0.5x EV/Revenues, 5.4x EV / Adj. EBITDA and c.8.0x Adj. PER (consensus forecasts, all Calendar 2027E – "cal 2027E").
- This is at the low end of McBride's historic trading range (average PER 13.6x for 2019-2024 excluding 2021/2022 losses) and is significantly lower than other consumer stocks. Whilst the continued input cost inflation is not helpful, we expect McBride to rerate once investor confidence in its longer-term strategic strength recovers.
- As McBride has no direct comparable companies we take a wide basket of 16 consumer stocks, split into three groups, and conclude McBride's fair value should at least equate to c.6x EV/EBITDA and 11x PER (cal 2027).
- **We reduce our Fair value per share from 265p to 230p.**

A profitable and cashflow generative market leader in private label household cleaning

Over 8% Adj. EBITDA margin driving cashflow from FY28E


- McBride's robust business model has generated revenues of over £900m and adj. operating profits of c.£60m-£65m for FY24-FY26 (6%-7% operating margin) – a step change from FY15-FY21.
- Although we forecast input cost inflation leading to Adj. operating profit falling to c.£48m in FY27E (4.7% margin), we anticipate some margin recovery actions driving operating profit margin back above 6% from FY28E.
- We forecast c.80%-95% conversion from Adj. EBITDA to adj. operating cashflow of £50m-£100m p/a (FY27E-FY29E) allowing for c.£30m-£40m capex investment p/a, the return of dividends, share buybacks and acquisitions.

A step-change in Adj. operating profit since FY23



Source: Company data, Equity Development

Tailored divisional strategies driving higher profit margins



Source: Company data, Equity Development

Very high conversion of profits to adj. operating cash



Source: Company data, Equity Development

Strategically important acquisition of Eurotab group…

A complementary and strategically aligned acquisition…

- In line with its growth strategy, McBride announced a binding offer for Eurotab Group ("Eurotab") in April 2026, a leading privately-owned manufacturer of cleaning "solid-format" tablets including dishwashing tablets, using precision powder compaction technology. The group also manufactures moisture absorbing solutions and disinfecting bleach tablets.
- Operating its two main specialised factories in France and a smaller one in Turkey, Eurotab will strengthen McBride's position as a leading European detergent producer by expanding product lines, deepening customer relationships and adding new markets.
- In addition, Eurotab has free production capacity that will help address McBride's capacity constraints within McBride's highly profitable unit dosing division. This will support future growth (with lower capex requirements) and enhance security of supply and customer service levels.

A market leader in cleaning tablets



Source: Company data, Equity Development

…at an attractive €40m price, just 0.6x EV/Revenues…

- The anticipated purchase price is €38.2m, dependent on Eurotab's closing 12-month EBITDA at completion, plus €1.8m for acquired tax losses (which are much higher).
- For the year-ended 30 June 2026, Eurotab is expected to report €65m revenue implying an EV/Revenue multiple of 0.6x.
- For more detail see our report: A strategic earnings-accretive acquisition.

Source: Company data, Equity Development

…and 3.1x EBITDA post synergies

- The expected purchase price (€38.2m) also represents an underlying EBITDA multiple of 5.2x (implying EBITDA of c.€7.3m and EBITDA margin of 11.2%) or 4.6x net of the value of acquired tax losses which the Group expects to use over time.
- What's more, the total acquisition price is only c. 3.1x EBITDA post synergies, suggesting EBITDA of up to €13m or £11m by FY29E. We estimate the synergies will accrue over 3 years, with more in FY28E and FY29E.

Source: Company data, Equity Development

…and an important contract manufacturing partnership with Vestacy

A transformational business win

- In line with its growth strategy, McBride announced in August 2026 it had secured two long-term (5-8 year) contract manufacturing agreements with E.H. Group B.V. (Vestacy).
- McBride will manufacture a variety of household products which are currently produced by a third-party supplier for Vestacy and are focused on the laundry markets (a strategic priority for McBride). Calgon is the leading water softener for washing machines and Woolite is a leading laundry brand for wools.
- McBride will also acquire two dedicated manufacturing facilities in Spain and Portugal for a nominal consideration and produce from several of its own European sites, to optimise efficiency and product travel times.

Market-leading brands across several categories



Source: Company data

Vestacy, owned by Advent International, ex Reckitt

- Vestacy was born out of the disposal by Reckitt Benckiser Group plc ("Reckitt") of its "Essential Home" business to private equity investor Advent International, L.P. in July 2025, for up to US$4.8bn (of which up to $1.3bn was deferred and contingent consideration). Reckitt continues to own 30%.
- The two factories in Granollers (Spain) and Porto Alto (Portugal) are expected to transfer to McBride in early calendar 2027 and the new capacity across the other McBride sites is expected to be fully operational in early calendar 2028.

Partnership funded by both parties


- Vestacy will fund most of the additional equipment required for capacity needs across the McBride production network, totalling £34m (€40m) which minimises the upfront capital requirement for McBride.
- McBride will fund c.£12m (€14m) transition and project costs (FY26E-FY28E with most falling in FY27E) and c.£5m specific capex over FY27E-FY28E, with most falling in FY28E.
- For more detail see our report: Strategic partnership drives FY29E PBT uplift.

An underrated business with high returns, despite pricing time lag hitting profits

Rating below our 230p/share fair value


- With the recovery in profits, alongside strategic investment in facilities, technology, partnerships and acquisitions, has come a step change in return on capital employed ("ROCE") to above 25%+ (adj. operating profits / adj. capital employed; management's internal target is 25%; FY26 27%). Even with the cost increases and time-lag we forecast c.25% ROCE by FY29E.
- Yet despite improving profitability, reinstating a dividend and announcing a £20m share buy-back, along with the Eurotab acquisition and Vestacy partnership, McBride trades on 0.4x cal 2027 EV/Revenues and c.8.5x cal 2027 PER.
- Our reduced Fair Value of 230p per share equates to undemanding valuation multiples of 0.5x EV/Revenues, c.6x EV/Adj. EBITDA, and c.11x PER (all cal 2027).

Adj. ROCE forecast build to 25%, in-line with 25% target




FY22 was loss-making; Source: Company data, Equity Development

Net debt / Adj. EBITDA to peak at c.2.7x in FY27E



Source: Company data, Equity Development

Undervalued versus a wide range of consumer stocks



Source: Koyfin for consensus estimates, Equity Development

Financial Forecast tables

Changes to group forecasts resulting from profit warning

		New forecasts			Old forecasts			% Change		
Year-end 30 Jun (£m)	**2026A**	**2027E**	**2028E**	**2029E**	**2027E**	**2028E**	**2029E**	**2027E**	**2028E**	**2029E**
Group Revenue	934.2	1,028.0	1,143.4	1,204.8	1,035.5	1,159.5	1,221.2	-0.7	-1.4	-1.3
Revenue growth (%)	*0.8*	*10.0*	*11.2*	*5.4*	*10.8*	*12.0*	*5.3*			
Adj. EBITDA	80.0	70.8	97.1	106.6	84.0	106.3	115.3	-15.7	-8.6	-7.6
Adj. EBITDA margin (%)	*8.6*	*6.9*	*8.5*	*8.8*	*8.1*	*9.2*	*9.4*			
Adj. EBIT	59.0	48.4	69.5	78.7	61.6	78.6	87.3	-21.5	-11.6	-9.9
Adj. EBIT margin (%)	*6.3*	*4.7*	*6.1*	*6.5*	*5.9*	*6.8*	*7.2*			
Adj. PBT	48.8	35.4	56.1	65.3	48.6	65.7	74.5	-27.2	-14.7	-12.4
Adj. PBT margin (%)	*5.2*	*3.4*	*4.9*	*5.4*	*4.7*	*5.7*	*6.1*			
Adjusted diluted EPS (p)	20.6	15.9	25.5	28.5	21.7	29.7	32.5	-26.6	-14.2	-12.4
Adj. EPS growth (%)	*(2.1)*	*(22.8)*	*59.9*	*11.9*	*5.2*	*36.7*	*9.6*			
DPS (p)	3.1	3.1	4.5	5.0	3.3	4.5	4.9			
Capex	30.9	33.3	37.1	39.1	33.6	37.6	39.6	-1	-1	-1
Free cashflow (ex M&A)	(2.0)	(10.2)	20.5	23.3	(0.8)	26.7	29.8	n/m	-23	-22
Net financial cash / (debt)	(116.7)	(181.7)	(171.6)	(161.0)	(172.4)	(156.3)	(139.2)	5	10	16
Total net cash /(debt) incl leases	(122.8)	(187.9)	(177.8)	(167.3)	(178.5)	(162.5)	(145.5)	5	9	15
Net financial cash / (debt) / Adj. EBITDA (x)	(1.5)	(2.6)	(1.8)	(1.5)	(2.1)	(1.5)	(1.2)			
Total net cash / (debt) / Adj. EBITDA (x)	(1.5)	(2.7)	(1.8)	(1.6)	(2.1)	(1.5)	(1.3)			

Note: Forecasts assume the proposed Eurotab acquisition is completed on 30 June 2026 and consolidated from 1 July 2026; Source: Company data, Equity Development

Divisional revenue analysis

Year-end 30 June (£m)	2022A	2023A	2024A	2025A	2026A	2027E	2028E	2029E
Liquids	383.9	497.9	532.8	529.6	526.0	553.2	655.3	705.2
Unit dosing	171.5	234.2	233.6	228.9	226.3	284.1	284.1	287.0
Powders	68.6	85.9	92.8	85.5	88.7	87.8	92.7	92.2
Aerosols	31.9	46.2	50.9	58.9	67.3	76.0	83.5	91.9
Asia Pacific	22.4	24.8	24.7	23.6	25.9	26.9	27.7	28.5
Total revenue	**678.3**	**889.0**	**934.8**	**926.5**	**934.2**	**1,028.0**	**1,143.4**	**1,204.8**
Group revenue growth (%)	(0.6)	31.1	5.2	(0.9)	0.8	10.0	11.2	5.4
Group FX impact (%)	(3.5)	2.7	(1.0)	(1.6)	2.6	0.8	0.0	0.0
Liquids	5.6	27.3	7.7	0.9	(3.1)	4.4	18.5	7.6
Unit dosing (organic)	(1.9)	33.9	0.7	(0.3)	(3.8)	0.0	0.0	1.0
Powders	7.2	22.7	9.2	(6.0)	0.7	(1.7)	5.6	(0.5)
Aerosols	(2.1)	40.8	11.6	18.3	10.5	12.0	10.0	10.0
Asia Pacific	(6.7)	6.9	8.3	(5.6)	7.5	3.0	3.0	3.0
Organic revenue growth, ex FX (%)	**2.9**	**28.4**	**6.2**	**0.7**	**(1.8)**	**3.2**	**11.2**	**5.4**
Liquids		5.0	6.6	3.5	0.5	6.4	20.5	9.6
Unit dosing		13.2	6.2	2.4	(3.0)	2.0	2.0	3.0
Powders		(9.5)	(3.9)	(4.4)	2.0	0.3	7.6	1.5
Aerosols			6.6	21.4	15.0	10.0	10.0	10.0
Asia Pacific			9.0	6.3	0.0	5.0	5.0	5.0
Organic sales volume growth (%)		**5.6**	**5.7**	**4.3**	**0.7**	**5.0**	**13.1**	**7.2**
Implied group price/mix effect (%)		**22.8**	0.5	(3.6)	(2.3)	(1.7)	(1.9)	(1.9)

Note: Organic growth includes the partnership with Vestacy but excludes the acquisition of Eurotab; Source: Company data, Equity Development

- We forecast that the delay in passing on input cost inflation leads to operating profit margin falling to 4.7% in FY27E (from 6%-7% in FY24-FY26), though management's medium term margin ambitions are higher. At the group's 2024 capital markets event, management set out medium term operating margin targets of: 7%-10% for Liquids; 8%-11% for Unit dosing; 4%-7% for Powders; 7%-10% for Aerosols and 9%-12% for Asia-Pacific. FY26 is the third year of the 5-year cost savings programme with the savings back-end weighted to years 4 / 5 (i.e. FY27E / FY28E). For every £1m of cost saving that is retained, operating profit increases by 1.5%.

Divisional operating profit analysis

Year-end 30 June (£m)	2022A	2023A	2024A	2025A	2026A	2027E	2028E	2029E
Liquids	(15.9)	10.5	45.6	41.0	31.4	23.6	37.5	43.9
Unit dosing	(0.8)	10.0	19.4	22.5	23.8	24.2	30.4	32.2
Powders	(2.5)	(0.7)	6.0	6.8	5.7	3.9	4.8	5.2
Aerosols	(1.5)	0.3	2.1	3.1	3.6	4.4	5.4	6.4
Asia Pacific	0.7	1.1	1.4	1.1	1.3	1.5	1.7	1.9
Corporate costs	(4.5)	(7.7)	(7.4)	(8.4)	(6.8)	(9.3)	(10.3)	(10.8)
Total operating profit	**(24.5)**	**13.5**	**67.1**	**66.1**	**59.0**	**48.4**	**69.5**	**78.7**
Liquids	(4.1)	2.1	8.6	7.7	6.0	4.3	5.7	6.2
Unit dosing	(0.5)	4.3	8.3	9.8	10.5	8.5	10.7	11.2
Powders	(3.6)	(0.8)	6.5	8.0	6.4	4.4	5.1	5.6
Aerosols	(4.7)	0.6	4.1	5.3	5.3	5.8	6.4	6.9
Asia Pacific	3.1	4.4	5.7	4.7	5.0	5.5	6.1	6.6
Corporate	(0.7)	(0.9)	(0.8)	(0.9)	(0.7)	(0.9)	(0.9)	(0.9)
Total operating profit margin (%)	**(3.6)**	**1.5**	**7.2**	**7.1**	**6.3**	**4.7**	**6.1**	**6.5**
Liquids			37.8	40.5	27.0			
Unit dosing			32.8	35.4	38.0			
Powders			21.5	30.0	28.6			
Aerosols			17.7	23.1	21.4			
Asia Pacific			15.9	15.1	15.3			
Adjusted ROCE*	**(11.5)**	**6.4**	**33.5**	**33.0**	**27.3**	**18.6**	**23.4**	**25.2**

*Note: * Adj. Operating profit / Average capital employed (%); Source: Company data, Equity Development*

- We expect 0%-2% organic revenue growth FY27E-FY29E comprising 1%-4% volume growth offset by pricing investment/mix of c.2% (this may change depending upon how long temporary price increases last). This is then supplemented by the partnership with Vestacy building scale and the acquisition of Eurotab. Management's ambition is 2% organic revenue growth p/a with medium term volume growth of 4% in Liquids; 3%-4% in Unit dosing; flat volumes in Powders, over 10% volume growth in Aerosols and 8% volume growth in Asia-Pacific.
- We forecast Adj. PBT falling by 27% to £35m in FY27E and then growth from the Vestacy partnership, the Eurotab acquisition, organic operating profit growth and financial deleveraging.

Key group growth and margin metrics

Year-end 30 June	2022A	2023A	2024A	2025A	2026A	2027E	2028E	2029E
Revenue growth (%)	(0.6)	31.1	5.2	(0.9)	0.8	10.0	11.2	5.4
Gross profit growth (%)	(19.5)	38.2	32.0	(1.7)	0.7	10.0	12.4	5.4
Adj. EBITDA growth (%)	n/m	n/m	155	(1.5)	(6.8)	(11.5)	37.2	9.7
Adj. Operating profit (%)	n/m	n/m	397	(1.5)	(10.7)	(18.0)	43.6	13.2
Adj. PBT growth (%)	n/m	n/m	n/m	3.4	(11.1)	(27.4)	58.3	16.4
Adj. EPS growth (%)	n/m	n/m	n/m	(2.7)	(2.1)	(22.8)	59.9	11.9
DPS growth (%)					3.3	0.0	45.0	11.9
Gross profit margin (%)	28.1	29.7	37.2	36.9	36.9	36.9	37.3	37.3
Adj. EBITDA margin (%)	(0.5)	3.8	9.3	9.3	8.6	6.9	8.5	8.8
Adj. Operating margin (%)	(3.6)	1.5	7.2	7.1	6.3	4.7	6.1	6.5
Adj. PBT margin (%)	(4.4)	0.0	5.7	5.9	5.2	3.4	4.9	5.4
Distribution costs / revenues (%)	9.5	8.8	8.7	9.2	9.4	9.4	9.3	9.3
Administrative costs / revenues (%)	21.9	18.9	21.0	20.6	21.2	22.8	21.9	21.5
Op costs incl D&A / revenues (%)	32.1	28.5	30.3	30.2	31.4	33.3	31.6	31.2
D&A / revenues (%)	3.1	2.3	2.1	2.1	2.2	2.2	2.4	2.3
Op costs excl D&A / revenues (%)	28.7	25.8	27.9	27.7	28.3	30.0	28.8	28.4
Tax rate (adj.) (%)	31.4	n/m	27.9	31.5	24.8	22.5	21.8	24.8

Source: Company data, Equity Development

- We see Group Adj. PBT rising to c.£65m by FY29E, after the temporary profit impact in FY26-FY28E, and Adj. EPS rising to c.28.5p in FY29E, a CAGR of 11%:

Income statement

Year-end 30 June (£m)	2022A	2023A	2024A	2025A	2026A	2027E	2028E	2029E
Group revenue	**678.3**	**889.0**	**934.8**	**926.5**	**934.2**	**1,028.0**	**1,143.4**	**1,204.8**
Cost of sales	(487.5)	(625.4)	(586.9)	(584.4)	(589.7)	(648.9)	(717.2)	(755.7)
Gross profit	190.8	263.6	347.9	342.1	344.5	379.1	426.2	449.1
Distribution costs	(64.3)	(77.9)	(81.3)	(85.5)	(87.7)	(96.5)	(106.2)	(111.9)
Administrative costs	(148.8)	(168.4)	(196.3)	(190.5)	(197.8)	(234.2)	(250.5)	(258.5)
Impairment losses / losses on PPE disposal	(2.2)	(3.8)	(3.2)	0.0	0.0	0.0	0.0	0.0
Add back: D&A	20.9	20.6	20.0	19.7	21.0	22.4	27.7	27.9
Operating costs, Adj. ex D&A	(194.4)	(229.5)	(260.8)	(256.3)	(264.5)	(308.3)	(329.1)	(342.5)
Adj. EBITDA	**(3.6)**	**34.1**	**87.1**	**85.8**	**80.0**	**70.8**	**97.1**	**106.6**
Depreciation & amortisation	(20.9)	(20.6)	(20.0)	(19.7)	(21.0)	(22.4)	(27.7)	(27.9)
Adj. Operating profit	**(24.5)**	**13.5**	**67.1**	**66.1**	**59.0**	**48.4**	**69.5**	**78.7**
Finance costs	(5.1)	(13.2)	(14.0)	(11.2)	(10.2)	(13.0)	(13.4)	(13.4)
Adj. PBT	**(29.6)**	**0.3**	**53.1**	**54.9**	**48.8**	**35.4**	**56.1**	**65.3**
Amortisation of acquired intangible assets	(2.6)	(2.4)	(2.0)	(1.9)	(1.3)	(1.3)	(1.3)	(1.3)
Exceptional operating costs	(2.4)	(0.8)	(0.8)	(4.0)	(7.6)	(11.7)	(5.0)	(5.0)
Exceptional finance costs	(3.5)	(12.2)	(3.8)	0.0	0.0	0.0	0.0	0.0
PBT	(35.3)	(15.1)	46.5	49.0	**39.9**	**22.4**	**49.8**	**59.0**
Tax	11.3	3.6	(13.2)	(15.8)	(9.9)	(5.3)	(11.1)	(14.9)
Adj. PAT	(20.3)	(0.0)	38.3	37.6	**36.7**	**27.4**	**43.9**	**49.1**
Reported PAT	(24.0)	(11.5)	33.3	33.2	30.0	17.0	38.6	44.0
No of f/d shares (m)	174.0	174.1	176.9	178.5	177.9	172.2	172.2	172.2
Adjusted diluted EPS (p)	**-11.7**	**0.0**	**21.7**	**21.1**	**20.6**	**15.9**	**25.5**	**28.5**
DPS (p)				**3.0**	**3.1**	**3.1**	**4.5**	**5.0**

Source: Company data, Equity Development

- After capex of c.£30m-£40m, dividend payments of c.£5m-£8m and c.£5m+ on share buybacks for the employee benefit trust ("EBT") we forecast c.£10m of net cashflow p/a from FY28E, to reduce net debt or fund acquisitions (after the £34.5m in FY27E), or further shareholder returns (after the anticipated £20m buy-back in FY26/FY27E).

Cashflow statement

Year-end 30 June (£m)	2022A	2023A	2024A	2025A	2026A	2027E	2028E	2029E
Adj. EBITDA, pre SBP	**(3.6)**	**34.1**	**87.1**	**85.8**	**80.0**	**70.8**	**97.1**	**106.6**
Add back: Share based payments charge	0.0	0.5	1.6	1.6	1.6	1.8	1.9	2.1
Change in inventories	(25.7)	(2.7)	0.6	(2.4)	(8.4)	(18.3)	(10.9)	(8.7)
Change in trade receivables*	(27.4)	(1.3)	(5.2)	9.9	(2.3)	(14.3)	(17.6)	(9.3)
Change in trade payables*	37.8	11.1	0.0	6.2	(9.0)	22.2	25.6	14.4
Working capital movement	(15.3)	7.1	(4.6)	13.7	**(19.7)**	**(10.4)**	**(2.9)**	**(3.6)**
Pension scheme funding	(4.0)	(4.0)	(4.0)	(7.0)	(5.7)	(5.7)	(5.7)	(5.7)
Other		0.3	1.6	(0.2)	0.5			
Adj. free operating cashflow	**(22.9)**	**38.0**	**81.7**	**93.9**	**56.7**	**56.4**	**90.5**	**99.4**
Net financial interest paid	(2.7)	(11.1)	(10.5)	(7.5)	(6.9)	(12.7)	(13.1)	(13.1)
Interest paid on lease liabilities	(0.4)	(0.3)	(0.3)	(0.4)	(0.4)	(0.3)	(0.3)	(0.3)
Lease payments (principal)	(5.0)	(4.3)	(4.5)	(4.2)	(4.5)	(3.3)	(3.5)	(3.7)
Tax paid	(0.1)	(1.8)	(5.1)	(17.9)	(7.8)	(5.3)	(11.1)	(14.9)
Exceptionals (cash)	(4.1)	(1.4)	(1.0)	(3.2)	(7.6)	(11.7)	(5.0)	(5.0)
Other incl refinancing costs	(1.8)	(12.3)	(5.5)	(1.8)	(0.6)			
Capex incl M&A (net)	(7.8)	(11.6)	(18.5)	(30.0)	(30.9)	(67.8)	(37.1)	(39.1)
Free cashflow	**(44.8)**	**(4.8)**	**36.3**	**28.9**	**(2.0)**	**(44.7)**	**20.5**	**23.3**
Dividends					(5.2)	(5.3)	(5.3)	(7.7)
Share buy backs / equity issues	(0.2)	0.0	(2.8)	(2.4)	(12.8)	(15.0)	(5.0)	(5.0)
Other (incl. FX)	(0.5)	(0.7)	0.2	(0.2)				
Net cashflow	**(45.5)**	**(5.5)**	**33.7**	**26.3**	**(20.0)**	**(65.0)**	**10.1**	**10.6**

Source: Company data, Equity Development

Net debt metrics

Year-end 30 June (£m)	2022A	2023A	2024A	2025A	2026A	2027E	2028E	2029E
Gross financial debt	(156.9)	(159.1)	(132.4)	(131.1)	(181.9)	(191.9)	(191.9)	(191.9)
Net cash	4.5	1.6	9.3	34.2	65.2	10.2	20.3	30.9
Net financial cash / (debt)	**(152.4)**	**(157.5)**	**(123.1)**	**(96.9)**	**(116.7)**	**(181.7)**	**(171.6)**	**(161.0)**
Leases	(12.0)	(9.0)	(8.4)	(8.3)	(6.1)	(6.2)	(6.2)	(6.3)
Total net cash /(debt) incl leases	**(164.4)**	**(166.5)**	**(131.5)**	**(105.2)**	**(122.8)**	**(187.9)**	**(177.8)**	**(167.3)**
Net financial (cash) / debt / Adj. EBITDA (x)	(42.3)	4.6	1.4	1.1	1.5	2.6	1.8	1.5
Total net (cash) / debt / Adj. EBITDA (x)	**(45.7)**	**4.9**	**1.5**	**1.2**	**1.5**	**2.7**	**1.8**	**1.6**

Source: Company data, Equity Development

Balance sheet: Assets

Year-end 30 June (£m)	2022A	2023A	2024A	2025A	2026A	2027E	2028E	2029E
Property, plant and equipment	122.9	117.8	114.4	120.3	123.5	160.8	160.9	162.4
Right of use assets	11.3	8.5	8.1	7.9	5.7	6.1	6.5	6.9
Goodwill	19.7	19.7	19.7	19.8	19.8	19.8	19.8	19.8
Intangible assets	7.3	6.5	9.8	18.3	28.3	38.1	49.2	60.9
Derivative financial instruments	1.9	4.5	1.7	0.3	0.1	0.1	0.1	0.1
Deferred tax assets & other tax assets	29.7	41.6	42.8	38.2	41.2	41.2	41.2	41.2
Non-current assets	**192.8**	**198.6**	**196.5**	**204.8**	**218.6**	**266.0**	**277.7**	**291.3**
Inventories	118.9	121.5	119.6	123.4	132.6	150.9	161.8	170.5
Trade and other receivables	145.4	145.7	148.8	139.1	142.2	156.5	174.0	183.4
Current tax assets	3.9	2.3	2.1	3.6	1.1	1.1	1.1	1.1
Other financial (derivative) assets	0.6	0.6	0.3	0.2	0.5	0.5	0.5	0.5
Cash & cash equivalents	4.5	1.6	9.3	34.2	65.2	10.2	20.3	30.9
Current assets	**273.3**	**271.7**	**280.1**	**300.5**	**341.6**	**319.2**	**357.7**	**386.3**

Source: Company data, Equity Development

Balance sheet: Liabilities

Year-end 30 June (£m)	2022A	2023A	2024A	2025A	2026A	2027E	2028E	2029E
Bank overdraft & s/t loans	(60.5)	(49.3)	(67.4)	(69.8)	(76.8)	(86.8)	(86.8)	(86.8)
Trade payables and other liabilities	(206.9)	(219.6)	(220.1)	(228.0)	(220.9)	(243.1)	(268.6)	(283.1)
Lease liabilities	(3.9)	(3.5)	(3.1)	(3.7)	(2.2)	(2.2)	(2.2)	(2.2)
Current tax liabilities	(5.3)	(6.7)	(12.9)	(7.2)	(9.0)	(9.0)	(9.0)	(9.0)
Provisions	(3.4)	(2.7)	(2.2)	(2.7)	(1.5)	(1.5)	(1.5)	(1.5)
Other financial liabilities	0.0	(1.8)	(0.4)	(0.4)	(0.3)	(0.3)	(0.3)	(0.3)
Current liabilities	**(280.0)**	**(283.6)**	**(306.1)**	**(311.8)**	**(310.7)**	**(342.9)**	**(368.4)**	**(382.9)**
Capital employed	**186.1**	**186.7**	**170.5**	**193.5**	**249.5**	**242.3**	**267.0**	**294.7**
Bank borrowings	(96.4)	(109.8)	(65.0)	(61.3)	(105.1)	(105.1)	(105.1)	(105.1)
Lease liabilities	(8.1)	(5.5)	(5.3)	(4.6)	(3.9)	(4.0)	(4.0)	(4.1)
Deferred tax liabilities	(4.7)	(5.1)	(6.0)	(6.7)	(7.1)	(7.1)	(7.1)	(7.1)
Provisions	(3.8)	(2.6)	(1.4)	(1.6)	(2.4)	(2.4)	(2.4)	(2.4)
Post employment benefits	(16.1)	(26.6)	(29.4)	(24.9)	(19.9)	(14.2)	(8.5)	(2.8)
Other financial liabilities				(0.1)	0.0	0.0	0.0	0.0
Non-current liabilities	**(129.1)**	**(149.6)**	**(107.1)**	**(99.2)**	**(138.4)**	**(132.8)**	**(127.1)**	**(121.5)**
Net assets	**57.0**	**37.1**	**63.4**	**94.3**	**111.1**	**109.6**	**139.8**	**173.2**
Shareholders' funds	**57.0**	**37.1**	**63.4**	**94.3**	**111.1**	**109.6**	**139.8**	**173.2**

Source: Company data, Equity Development

Contacts

Andy Edmond
Direct: 020 7065 2691
Tel: 020 7065 2690
andy@equitydevelopment.co.uk

Hannah Crowe
Direct: 0207 065 2692
Tel: 0207 065 2690
hannah@equitydevelopment.co.uk

Equity Development Limited is regulated by the Financial Conduct Authority

Disclaimer

Equity Development Limited ('ED') is retained to act as financial adviser for its corporate clients, some or all of whom may now or in the future have an interest in the contents of this document. ED produces and distributes research for these corporate clients to persons who are not clients of ED. In the preparation of this report ED has taken professional efforts to ensure that the facts stated herein are clear, fair and not misleading, but makes no guarantee as to the accuracy or completeness of the information or opinions contained herein.

Any reader of this research should not act or rely on this document or any of its contents. This report is being provided by ED to provide background information about the subject of the research to relevant persons, as defined by the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever.

Research produced and distributed by ED on its client companies is normally commissioned and paid for by those companies themselves ('issuer financed research') and as such is not deemed to be independent as defined by the FCA but is 'objective' in that the authors are stating their own opinions. This document is prepared for clients under UK law. In the UK, companies quoted on AIM are subject to lighter due diligence than shares quoted on the main market and are therefore more likely to carry a higher degree of risk than main market companies.

ED may in the future provide, or may have in the past provided, investment banking services to the subject of this report. ED, its directors or persons connected may at some time in the future have, or have had in the past, a material investment in the Company. ED, its affiliates, officers, directors and employees, will not be liable for any loss or damage arising from any use of this document to the maximum extent that the law permits.

More information is available on our website www.equitydevelopment.co.uk